Is mastectomy with immediate reconstruction safe for patients undergoing neoadjuvant chemotherapy? A nationwide study from Korean Breast Cancer Society

Breast Cancer ◽  
2021 ◽  
Author(s):  
Sungmin Park ◽  
Joon Jeong ◽  
Wonshik Han ◽  
Young Joo Lee ◽  
Hyun-Ah Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Immediate Reconstruction ◽  
Cancer Society ◽  
Nationwide Study

Is There a Bias Against Obese Patients in the Treatment of Breast Cancer?

2020 ◽  
pp. 000313482098487
Author(s):  
Melinda Wang ◽  
Julian Huang ◽  
Anees B. Chagpar
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Prophylactic Mastectomy ◽  
Implicit Bias ◽  
Treatment Decision ◽  
Obese Patients ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Immediate Reconstruction

Background Patient and tumor characteristics often coincide with obesity, potentially affecting treatment decision-making in obese breast cancer patients. Independent of all of these factors, however, it is unclear whether obesity itself impacts the decision to offer patients undergoing mastectomy breast reconstruction, postmastectomy radiation therapy (PMRT), or neoadjuvant chemotherapy. We sought to determine whether implicit bias against obese breast cancer patients undergoing mastectomy plays a role in their treatment. Methods Medical records of breast cancer patients undergoing mastectomy from January 2010 to April 2018 from a single institution were retrospectively reviewed, separated into obese (BMI ≥30) and nonobese (BMI <30) categories, and compared using nonparametric statistical analyses. Results Of 972 patients, 291 (31.2%) were obese. Obese patients were more likely to have node-positive, triple-negative breast cancers ( P = .026) and were also more likely to have other comorbidities such as a history of smoking ( P = .026), hypertension ( P < .001), and diabetes ( P < .001). Receipt of immediate reconstruction and contralateral prophylactic mastectomy did not vary between obese and nonobese patients. While obese patients were more likely to undergo neoadjuvant chemotherapy (26.5% vs. 18.1%, P = .004) and PMRT (33.0% vs. 23.4%, P = .003), this did not remain significant when controlling for comorbidities and clinicopathologic confounders. Conclusion Obese patients present with more aggressive tumors and often have concomitant comorbidities. Independent of these factors, however, differences in the treatment of patients undergoing mastectomy do not seem to be affected by an implicit bias against obese patients.

Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society

2017 ◽  
Vol 34 (6) ◽  
Author(s):  
Sungmin Park ◽  
◽  
Ku Sang Kim ◽  
Jeong-Soo Kim ◽  
Wonshik Han ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Value ◽  
Young Patients ◽  
Cancer Society ◽  
Nationwide Study ◽  
Blood Types

Oncologic Outcomes of Nipple-sparing Mastectomy and Immediate Reconstruction After Neoadjuvant Chemotherapy for Breast Cancer

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Zhen Yu Wu ◽  
Hee-Jeong Kim ◽  
Jong-Won Lee ◽  
Il-Yong Chung ◽  
Ji-Sun Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Oncologic Outcomes ◽  
Immediate Reconstruction ◽  
Nipple Sparing Mastectomy ◽  
Nipple Sparing

scholarly journals Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients

2019 ◽  
Vol 19 (6) ◽  
pp. e741-e747
Author(s):  
Devon Livingston-Rosanoff ◽  
Jessica Schumacher ◽  
Kara Vande Walle ◽  
Trista Stankowski-Drengler ◽  
Caprice C. Greenberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Tumor Size ◽  
Breast Cancer Patients ◽  
Nationwide Study ◽  
Modern Era ◽  
Response To Neoadjuvant Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document